Why the study?
The COVID-19 pandemic has profoundly changed clinical care and research, necessitating adaptation in the conduct of clinical trials and the clinical research ecosystem.
Provides expert consensus recommendations on adapting cardiovascular and heart failure clinical trials to the challenges posed by the COVID-19 pandemic.
Answers are grounded in this paper and cite their sources.
Facilitates resilient cardiovascular trial operations amid disruptions; extends consensus frameworks for decentralized monitoring and statistical adaptations.
The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment. The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory and the Academic Research Consortium, composed of academic investigators from the United States and Europe, patients, the U.S. Food and Drug Administration, the National Institutes of Health, and industry members. A series of meetings were convened to address the challenges caused by the COVID-19 pandemic, review options for maintaining or altering best practices, and establish key recommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart failure. This paper summarizes the discussions and expert consensus recommendations.
No takes yet. Share an insight, caveat, or question.
Psotka et al. (2020) conducted a review in Cardiovascular disease and heart failure. Expert consensus recommendations were established to address challenges and adapt the conduct and analysis of cardiovascular clinical trials during the COVID-19 pandemic.
Synapse has enriched 10 related papers. Consider them for comparative context: